337 related articles for article (PubMed ID: 35095765)
1. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.
Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
Front Endocrinol (Lausanne); 2021; 12():799382. PubMed ID: 35095765
[TBL] [Abstract][Full Text] [Related]
2. INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES.
Andrade VG; Yamashiro FDS; Oliveira CV; Moreira A; Winckler FC; Silva GF
Arq Gastroenterol; 2018; 55(3):274-278. PubMed ID: 30540091
[TBL] [Abstract][Full Text] [Related]
3. Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study.
Lee H; Chien RN; Pao LH; Kuo CJ; Huang PH; Chang ML
Cells; 2021 Oct; 10(11):. PubMed ID: 34831156
[TBL] [Abstract][Full Text] [Related]
4. The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents.
Huang JF; Huang CF; Yeh ML; Dai CY; Hsieh MH; Yang JF; Huang CI; Lin YH; Liang PC; Lin ZY; Chen SC; Yu ML; Chuang WL
Kaohsiung J Med Sci; 2017 Nov; 33(11):567-571. PubMed ID: 29050674
[TBL] [Abstract][Full Text] [Related]
5. The evolving relationship between adiponectin and insulin sensitivity in hepatitis C patients during viral clearance.
Chang ML; Kuo CJ; Pao LH; Hsu CM; Chiu CT
Virulence; 2017 Oct; 8(7):1255-1264. PubMed ID: 28267407
[TBL] [Abstract][Full Text] [Related]
6. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
Khattab M; Eslam M; Sharwae MA; Shatat M; Ali A; Hamdy L
Am J Gastroenterol; 2010 Sep; 105(9):1970-7. PubMed ID: 20234345
[TBL] [Abstract][Full Text] [Related]
7. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
Serfaty L; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Lonjon-Domanec I; DeMasi R; Picchio G; Beumont M; Marcellin P
Gut; 2012 Oct; 61(10):1473-80. PubMed ID: 22387529
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.
Adinolfi LE; Nevola R; Guerrera B; D'Alterio G; Marrone A; Giordano M; Rinaldi L
J Gastroenterol Hepatol; 2018 Jul; 33(7):1379-1382. PubMed ID: 29228501
[TBL] [Abstract][Full Text] [Related]
9. The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients.
Jung HJ; Kim YS; Kim SG; Lee YN; Jeong SW; Jang JY; Lee SH; Kim HS; Kim BS
Clin Mol Hepatol; 2014 Mar; 20(1):38-46. PubMed ID: 24757657
[TBL] [Abstract][Full Text] [Related]
10. Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4.
Khattab MA; Eslam M; Shatat M; Abd-Aalhalim H; Mousa YI; Samir F; Aly H; Shaker O; Shaker Y
J Gastrointestin Liver Dis; 2012 Mar; 21(1):59-65. PubMed ID: 22457861
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment.
Elhelbawy M; Abdel-Razek W; Alsebaey A; Hashim M; Elshenawy H; Waked I
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):16-23. PubMed ID: 30024489
[TBL] [Abstract][Full Text] [Related]
12. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3.
Thompson AJ; Patel K; Chuang WL; Lawitz EJ; Rodriguez-Torres M; Rustgi VK; Flisiak R; Pianko S; Diago M; Arora S; Foster GR; Torbenson M; Benhamou Y; Nelson DR; Sulkowski MS; Zeuzem S; Pulkstenis E; Subramanian GM; McHutchison JG;
Gut; 2012 Jan; 61(1):128-34. PubMed ID: 21873466
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance.
Russo FP; Zanetto A; Gambato M; Bortoluzzi I; Al Zoairy R; Franceschet E; De Marchi F; Marzi L; Lynch EN; Floreani A; Farinati F; Schaefer B; Burra P; Zoller H; Mega A
J Viral Hepat; 2020 Feb; 27(2):188-194. PubMed ID: 31596996
[TBL] [Abstract][Full Text] [Related]
14. The interaction between insulin resistance, liver fibrosis and early virological response in Egyptian patients with chronic hepatitis C.
Ziada DH; El Saadany S; Enaba M; Ghazy M; Hasan A
Can J Gastroenterol; 2012 Jun; 26(6):325-9. PubMed ID: 22720272
[TBL] [Abstract][Full Text] [Related]
15. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.
Dai CY; Huang JF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Hepatol; 2009 Apr; 50(4):712-8. PubMed ID: 19231011
[TBL] [Abstract][Full Text] [Related]
16. TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.
Petta S; Di Marco V; Di Stefano R; Cabibi D; Cammà C; Marchesini G; Craxì A
J Viral Hepat; 2011 Jul; 18(7):e372-80. PubMed ID: 21692950
[TBL] [Abstract][Full Text] [Related]
17. DOES INSULIN RESISTANCE IMPAIR THE VIROLOGICAL RESPONSE TO PEGINTERFERON/RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS?
Laurito MP; Silva GF; Cheinquer H; Sharma R; Verna E; Parise ER
Arq Gastroenterol; 2018; 55(2):179-183. PubMed ID: 30043870
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon plus ribavirin therapy improves pancreatic β-cell function in chronic hepatitis C patients.
Huang JF; Dai CY; Yu ML; Huang CF; Huang CI; Yeh ML; Yang JF; Hou NJ; Hsiao PJ; Lin ZY; Chen SC; Shin SJ; Chuang WL
Liver Int; 2011 Sep; 31(8):1155-62. PubMed ID: 21745292
[TBL] [Abstract][Full Text] [Related]
19. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
[TBL] [Abstract][Full Text] [Related]
20. Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?
Mousa N; Abdel-Razik A; Farag R; Shabana W; Elgamal A; El-Wakeel N; Elzehery R; Elkashef W; Eldars W
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1004-1009. PubMed ID: 28749790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
